Literature DB >> 8288629

A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5.

N Yamaguchi1, K Hattori, M Oh-eda, T Kojima, N Imai, N Ochi.   

Abstract

Sixty-four kinds of cell lines were examined for their ability to produce megakaryocyte potentiating activity by means of conditioned media obtained from a protein-free culture system. Six human tumor cell lines were shown to produce this activity, and the cell line HPC-Y5, established from human pancreatic cancer, was shown to have the highest level of activity. The megakaryocyte potentiating factor (MPF) was purified from an HPC-Y5 conditioned medium by a combination of ion-exchange chromatography, gel filtration and reverse-phase HPLC. The purified MPF showed a megakaryocyte potentiating activity almost equal to human interleukin-6 in the presence of murine interleukin-3 in a colony formation assay with mouse bone marrow cells. The apparent molecular weight of MPF is 32,000 when determined by SDS-polyacrylamide gel electrophoresis. Glycopeptidase F digestion, and amino sugar analysis of the factor demonstrated that MPF is a glycoprotein carrying at least one N-linked sugar chain. The N-terminal amino acid sequence of MPF was determined to be Leu-Ala-Gly-Glu-Thr-Gly-Gln-Glu-Ala-Ala-Pro-Leu- Asp-Gly-Val-Leu-Ala-Asn. The same or homologous amino acid sequence has not been found in known proteins, demonstrating that MPF is a novel cytokine that has megakaryocyte potentiating activity in the murine assay system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8288629

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  The continual search for ideal biomarkers for mesothelioma: the hurdles.

Authors:  Fraser J Brims; Y C Gary Lee; Jenette Creaney
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

3.  Diagnostic tumor marker of asbestos-related mesothelioma.

Authors:  Okio Hino; Masahiro Maeda
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

4.  Mesothelin is not required for normal mouse development or reproduction.

Authors:  T K Bera; I Pastan
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

5.  Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Authors:  Jingli Zhang; Shuo Qiu; Yujian Zhang; Maria Merino; Patricia Fetsch; Itzhak Avital; Armando Filie; Ira Pastan; Raffit Hassan
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

6.  Mesothelin expression in the leptomeninges and meningiomas.

Authors:  Mahlon D Johnson; Fran Vito; Mary J O'Connell
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

Review 7.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

8.  Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.

Authors:  Fabian Mc Johnston; Marcus C B Tan; Benjamin R Tan; Matthew R Porembka; Elizabeth M Brunt; David C Linehan; Peter O Simon; Stacey Plambeck-Suess; Timothy J Eberlein; Karl Erik Hellstrom; Ingegerd Hellstrom; William G Hawkins; Peter Goedegebuure
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

Review 9.  Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.

Authors:  Hui Liu; Licun Wu; Kai Ji; Wei Wang
Journal:  Tumour Biol       Date:  2015-09-11

10.  Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats.

Authors:  Bangalore K Sathyanarayana; Yoonsoo Hahn; Manish S Patankar; Ira Pastan; Byungkook Lee
Journal:  BMC Struct Biol       Date:  2009-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.